Literature DB >> 17157814

2-Keto-4-methylthiobutyrate, an intermediate in the methionine salvage pathway, is a good substrate for CtBP1.

Younes Achouri1, Gaëtane Noël, Emile Van Schaftingen.   

Abstract

In the present work, we have studied the kinetic properties of the catalytic domain of CtBP1, a co-repressor belonging to the d-2-hydroxyacid dehydrogenase family and known to reduce pyruvate in the presence of NADH. CtBP1 acted on a variety of alpha-keto acids, for which it displayed biphasic curves with inhibition at elevated concentrations, as observed with other dehydrogenases of the same family. Based on catalytic efficiencies, the best substrate was 2-keto-4-methylthiobutyrate, an intermediate of the methionine salvage pathway. It was about 20-fold better than 2-ketoisocaproate and glyoxylate, and 80-fold better than pyruvate. From these data we conclude that 2-keto-4-methylthiobutyrate may be an important regulator of CtBP activity, possibly linking gene repression to the activity of the methionine salvage and spermine synthesis pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17157814     DOI: 10.1016/j.bbrc.2006.11.111

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.

Authors:  Maya Berg; Raquel García-Hernández; Bart Cuypers; Manu Vanaerschot; José I Manzano; José A Poveda; José A Ferragut; Santiago Castanys; Jean-Claude Dujardin; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design.

Authors:  Brendan J Hilbert; Steven R Grossman; Celia A Schiffer; William E Royer
Journal:  FEBS Lett       Date:  2014-03-19       Impact factor: 4.124

3.  Assembly of human C-terminal binding protein (CtBP) into tetramers.

Authors:  Andrew G Bellesis; Anne M Jecrois; Janelle A Hayes; Celia A Schiffer; William E Royer
Journal:  J Biol Chem       Date:  2018-04-26       Impact factor: 5.157

4.  Structure-guided design of a high affinity inhibitor to human CtBP.

Authors:  Brendan J Hilbert; Benjamin L Morris; Keith C Ellis; Janet L Paulsen; Celia A Schiffer; Steven R Grossman; William E Royer
Journal:  ACS Chem Biol       Date:  2015-01-30       Impact factor: 5.100

5.  Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP).

Authors:  Sudha Korwar; Benjamin L Morris; Hardik I Parikh; Robert A Coover; Tyler W Doughty; Ian M Love; Brendan J Hilbert; William E Royer; Glen E Kellogg; Steven R Grossman; Keith C Ellis
Journal:  Bioorg Med Chem       Date:  2016-04-20       Impact factor: 3.641

6.  The oligomeric state of CtBP determines its role as a transcriptional co-activator and co-repressor of Wingless targets.

Authors:  Chandan Bhambhani; Jinhee L Chang; David L Akey; Ken M Cadigan
Journal:  EMBO J       Date:  2011-04-05       Impact factor: 11.598

7.  Therapeutic targeting of C-terminal binding protein in human cancer.

Authors:  Michael W Straza; Seema Paliwal; Ramesh C Kovi; Barur Rajeshkumar; Peter Trenh; Daniel Parker; Giles F Whalen; Stephen Lyle; Celia A Schiffer; Steven R Grossman
Journal:  Cell Cycle       Date:  2010-09-08       Impact factor: 4.534

8.  Incapacitating CtBP to kill cancer.

Authors:  Ling-Zun Zhao; G Chinnadurai
Journal:  Cell Cycle       Date:  2010-09-15       Impact factor: 4.534

Review 9.  The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target.

Authors:  Melanie A Blevins; Mingxia Huang; Rui Zhao
Journal:  Mol Cancer Ther       Date:  2017-06       Impact factor: 6.261

10.  Structurally related Arabidopsis ANGUSTIFOLIA is functionally distinct from the transcriptional corepressor CtBP.

Authors:  Mark D Stern; Hitoshi Aihara; Kiu-Hyung Cho; Gyung-Tae Kim; Gorou Horiguchi; Giorgio A Roccaro; Elizabeth Guevara; Huan Huan Sun; Dereje Negeri; Hirokazu Tsukaya; Yutaka Nibu
Journal:  Dev Genes Evol       Date:  2007-10-31       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.